ID   NEK9_HUMAN              Reviewed;         979 AA.
AC   Q8TD19; Q52LK6; Q8NCN0; Q8TCY4; Q9UPI4; Q9Y6S4; Q9Y6S5; Q9Y6S6;
DT   15-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=Serine/threonine-protein kinase Nek9;
DE            EC=2.7.11.1;
DE   AltName: Full=Nercc1 kinase;
DE   AltName: Full=Never in mitosis A-related kinase 9;
DE            Short=NimA-related protein kinase 9;
DE   AltName: Full=NimA-related kinase 8;
DE            Short=Nek8;
GN   Name=NEK9; Synonyms=KIAA1995, NEK8, NERCC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, PROTEIN SEQUENCE OF
RP   61-70; 318-327; 331-352 AND 511-530, MUTAGENESIS OF THR-210 AND
RP   THR-214, AND VARIANT HIS-429.
RC   TISSUE=Dendritic cell, and Fibroblast;
RX   PubMed=11864968; DOI=10.1074/jbc.M108662200;
RA   Holland P.M., Milne A., Garka K., Johnson R.S., Willis C., Sims J.E.,
RA   Rauch C.T., Bird T.A., Virca G.D.;
RT   "Purification, cloning, and characterization of Nek8, a novel NIMA-
RT   related kinase, and its candidate substrate Bicd2.";
RL   J. Biol. Chem. 277:16229-16240(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, PARTIAL PROTEIN
RP   SEQUENCE, AND MUTAGENESIS OF LYS-81.
RX   PubMed=12101123; DOI=10.1101/gad.972202;
RA   Roig J., Mikhailov A., Belham C., Avruch J.;
RT   "Nercc1, a mammalian NIMA-family kinase, binds the Ran GTPase and
RT   regulates mitotic progression.";
RL   Genes Dev. 16:1640-1658(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-429.
RC   TISSUE=Brain;
RX   PubMed=12056414; DOI=10.1093/dnares/9.2.47;
RA   Ohara O., Nagase T., Mitsui G., Kohga H., Kikuno R., Hiraoka S.,
RA   Takahashi Y., Kitajima S., Saga Y., Koseki H.;
RT   "Characterization of size-fractionated cDNA libraries generated by the
RT   in vitro recombination-assisted method.";
RL   DNA Res. 9:47-57(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION.
RX   PubMed=12840024; DOI=10.1074/jbc.M303663200;
RA   Belham C., Roig J., Caldwell J.A., Aoyama Y., Kemp B.E., Comb M.,
RA   Avruch J.;
RT   "A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the
RT   Nek6 and Nek7 kinases.";
RL   J. Biol. Chem. 278:34897-34909(2003).
RN   [7]
RP   FUNCTION, INTERACTION WITH SSRP1 AND SUPT16H, SUBCELLULAR LOCATION,
RP   AND PHOSPHORYLATION AT THR-210.
RX   PubMed=14660563; DOI=10.1074/jbc.M311477200;
RA   Tan B.C.-M., Lee S.-C.;
RT   "Nek9, a novel FACT-associated protein, modulates interphase
RT   progression.";
RL   J. Biol. Chem. 279:9321-9330(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   INTERACTION WITH NEK6.
RX   PubMed=19001501; DOI=10.1242/jcs.035360;
RA   Rapley J., Nicolas M., Groen A., Regue L., Bertran M.T., Caelles C.,
RA   Avruch J., Roig J.;
RT   "The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel
RT   site necessary for mitotic spindle formation.";
RL   J. Cell Sci. 121:3912-3921(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-76; THR-254;
RP   SER-741; SER-801; THR-886; SER-944 AND SER-978, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   FUNCTION.
RX   PubMed=19941817; DOI=10.1016/j.molcel.2009.09.038;
RA   Richards M.W., O'Regan L., Mas-Droux C., Blot J.M., Cheung J.,
RA   Hoelder S., Fry A.M., Bayliss R.;
RT   "An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7
RT   kinase is released through binding of Nek9.";
RL   Mol. Cell 36:560-570(2009).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-2; SER-13; SER-16; TYR-52; SER-76; THR-254;
RP   SER-801; SER-832; THR-886 AND SER-944, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20; THR-254; SER-331;
RP   THR-333; SER-868 AND SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13 AND SER-29, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   INVOLVEMENT IN NC, VARIANTS NC THR-167 AND THR-573, CHARACTERIZATION
RP   OF VARIANTS NC THR-167 AND THR-573, AND PHOSPHORYLATION AT THR-210.
RX   PubMed=27153399; DOI=10.1016/j.ajhg.2016.03.019;
RG   Yale Center for Mendelian Genomics;
RA   Levinsohn J.L., Sugarman J.L., McNiff J.M., Antaya R.J., Choate K.A.;
RT   "Somatic mutations in NEK9 cause nevus comedonicus.";
RL   Am. J. Hum. Genet. 98:1030-1037(2016).
RN   [21]
RP   INVOLVEMENT IN APUG, AND VARIANT APUG HIS-681.
RX   PubMed=26633546; DOI=10.1038/gim.2015.147;
RA   Shaheen R., Patel N., Shamseldin H., Alzahrani F., Al-Yamany R.,
RA   Almoisheer A., Ewida N., Anazi S., Alnemer M., Elsheikh M.,
RA   Alfaleh K., Alshammari M., Alhashem A., Alangari A.A., Salih M.A.,
RA   Kircher M., Daza R.M., Ibrahim N., Wakil S.M., Alaqeel A.,
RA   Altowaijri I., Shendure J., Al-Habib A., Faqieh E., Alkuraya F.S.;
RT   "Accelerating matchmaking of novel dysmorphology syndromes through
RT   clinical and genomic characterization of a large cohort.";
RL   Genet. Med. 18:686-695(2016).
RN   [22]
RP   INVOLVEMENT IN LCCS10.
RX   PubMed=26908619; DOI=10.1093/hmg/ddw054;
RA   Casey J.P., Brennan K., Scheidel N., McGettigan P., Lavin P.T.,
RA   Carter S., Ennis S., Dorkins H., Ghali N., Blacque O.E., Mc Gee M.M.,
RA   Murphy H., Lynch S.A.;
RT   "Recessive NEK9 mutation causes a lethal skeletal dysplasia with
RT   evidence of cell cycle and ciliary defects.";
RL   Hum. Mol. Genet. 25:1824-1835(2016).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 940-950 IN COMPLEXES WITH
RP   DYNLL1, AND INTERACTION WITH DYNLL1.
RX   PubMed=23482567; DOI=10.1074/jbc.M113.459149;
RA   Gallego P., Velazquez-Campoy A., Regue L., Roig J., Reverter D.;
RT   "Structural analysis of the regulation of the DYNLL/LC8 binding to
RT   Nek9 by phosphorylation.";
RL   J. Biol. Chem. 288:12283-12294(2013).
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-429; THR-828 AND SER-870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Pleiotropic regulator of mitotic progression,
CC       participating in the control of spindle dynamics and chromosome
CC       separation. Phosphorylates different histones, myelin basic
CC       protein, beta-casein, and BICD2. Phosphorylates histone H3 on
CC       serine and threonine residues and beta-casein on serine residues.
CC       Important for G1/S transition and S phase progression.
CC       Phosphorylates NEK6 and NEK7 and stimulates their activity by
CC       releasing the autoinhibitory functions of Tyr-108 and Tyr-97
CC       respectively. {ECO:0000269|PubMed:12840024,
CC       ECO:0000269|PubMed:14660563, ECO:0000269|PubMed:19941817}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated during mitosis by intramolecular
CC       autophosphorylation. Activity and autophosphorylation is activated
CC       by manganese >> magnesium ions. Sensitive to increasing
CC       concentration of detergents. It is not cell-cycle regulated but
CC       activity is higher in G0-arrested cells.
CC   -!- SUBUNIT: Homodimer. Binds to Ran GTPase. Has a greater affinity
CC       for Ran-GDP over Ran-GTP. Interacts with NEK6, NEK7 and BICD2.
CC       Interacts with SSRP1 and SUPT16H, the 2 subunits of the FACT
CC       complex. Interacts with DYNLL1; phosphorylation at Ser-944
CC       strongly reduces DYNLL1 binding. {ECO:0000269|PubMed:14660563,
CC       ECO:0000269|PubMed:19001501, ECO:0000269|PubMed:23482567}.
CC   -!- INTERACTION:
CC       P63167:DYNLL1; NbExp=4; IntAct=EBI-1044009, EBI-349105;
CC       O95166:GABARAP; NbExp=5; IntAct=EBI-1044009, EBI-712001;
CC       Q9H0R8:GABARAPL1; NbExp=6; IntAct=EBI-1044009, EBI-746969;
CC       P60520:GABARAPL2; NbExp=7; IntAct=EBI-1044009, EBI-720116;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1044009, EBI-352572;
CC       Q9GZQ8:MAP1LC3B; NbExp=2; IntAct=EBI-1044009, EBI-373144;
CC       Q9BXW4:MAP1LC3C; NbExp=2; IntAct=EBI-1044009, EBI-2603996;
CC       P53350:PLK1; NbExp=5; IntAct=EBI-1044009, EBI-476768;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14660563}.
CC       Nucleus {ECO:0000269|PubMed:14660563}.
CC   -!- TISSUE SPECIFICITY: Most abundant in heart, liver, kidney and
CC       testis. Also expressed in smooth muscle cells and fibroblasts.
CC   -!- DEVELOPMENTAL STAGE: Expression varied mildly across the cell
CC       cycle, with highest expression observed in G1 and stationary-phase
CC       cells.
CC   -!- DOMAIN: Dimerizes through its coiled-coil domain.
CC   -!- PTM: Autophosphorylated on serine and threonine residues
CC       (PubMed:27153399). When complexed with FACT, exhibits markedly
CC       elevated phosphorylation on Thr-210. During mitosis, not
CC       phosphorylated on Thr-210. Phosphorylated by CDK1 in vitro.
CC       {ECO:0000269|PubMed:14660563, ECO:0000269|PubMed:27153399}.
CC   -!- DISEASE: Lethal congenital contracture syndrome 10 (LCCS10)
CC       [MIM:617022]: A form of lethal congenital contracture syndrome, an
CC       autosomal recessive disorder characterized by degeneration of
CC       anterior horn neurons, extreme skeletal muscle atrophy and
CC       congenital non-progressive joint contractures. The contractures
CC       can involve the upper or lower limbs and/or the vertebral column,
CC       leading to various degrees of flexion or extension limitations
CC       evident at birth. {ECO:0000269|PubMed:26908619}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Nevus comedonicus (NC) [MIM:617025]: A rare type of
CC       epidermal nevus characterized by closely arranged, dilated,
CC       plugged follicular ostia in a honeycomb pattern. The plugged ostia
CC       contain lamellated keratinaceous material, and their appearance
CC       resembles black dots. NC may be non-pyogenic with an acne-like
CC       appearance or associated with the formation of cysts, papules,
CC       pustules, and abscesses. Most commonly it affects the face and
CC       neck area and, by exception, other anatomical regions, including
CC       genital area, palms, and soles. NC lesions might present with
CC       various patterns of distribution: unilateral, bilateral, linear,
CC       interrupted, segmental, or blaschkoid.
CC       {ECO:0000269|PubMed:27153399}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Arthrogryposis, Perthes disease, and upward gaze palsy
CC       (APUG) [MIM:614262]: An autosomal recessive, syndromic form of
CC       arthrogryposis, a disease characterized by persistent joints
CC       flexure or contracture. APUG patients manifest an unusual
CC       combination of arthrogryposis, upward gaze palsy, and avascular
CC       necrosis of the hip (Perthes disease).
CC       {ECO:0000269|PubMed:26633546}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr
CC       protein kinase family. NIMA subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD31936.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAC02704.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY048580; AAL05428.1; -; mRNA.
DR   EMBL; AY080896; AAL87410.1; -; mRNA.
DR   EMBL; AB082526; BAC02704.1; ALT_INIT; mRNA.
DR   EMBL; AC007055; AAD31936.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC007055; AAD31938.1; -; Genomic_DNA.
DR   EMBL; AC007055; AAD31939.1; -; Genomic_DNA.
DR   EMBL; AC007055; AAD31940.1; -; Genomic_DNA.
DR   EMBL; BC009336; AAH09336.2; -; mRNA.
DR   EMBL; BC093881; AAH93881.1; -; mRNA.
DR   EMBL; BC112101; AAI12102.1; -; mRNA.
DR   CCDS; CCDS9839.1; -.
DR   RefSeq; NP_001316166.1; NM_001329237.1.
DR   RefSeq; NP_001316167.1; NM_001329238.1.
DR   RefSeq; NP_149107.4; NM_033116.5.
DR   UniGene; Hs.624721; -.
DR   UniGene; Hs.7200; -.
DR   PDB; 3ZKE; X-ray; 2.20 A; B/D/F/H/J/L=940-950.
DR   PDB; 3ZKF; X-ray; 2.60 A; B/D/F/H/J/L=940-950.
DR   PDBsum; 3ZKE; -.
DR   PDBsum; 3ZKF; -.
DR   ProteinModelPortal; Q8TD19; -.
DR   SMR; Q8TD19; -.
DR   BioGrid; 124876; 32.
DR   IntAct; Q8TD19; 24.
DR   MINT; MINT-2984282; -.
DR   STRING; 9606.ENSP00000238616; -.
DR   BindingDB; Q8TD19; -.
DR   ChEMBL; CHEMBL5257; -.
DR   GuidetoPHARMACOLOGY; 2124; -.
DR   TCDB; 1.I.1.1.3; the nuclear pore complex (npc) family.
DR   iPTMnet; Q8TD19; -.
DR   PhosphoSitePlus; Q8TD19; -.
DR   BioMuta; NEK9; -.
DR   DMDM; 116242675; -.
DR   EPD; Q8TD19; -.
DR   MaxQB; Q8TD19; -.
DR   PaxDb; Q8TD19; -.
DR   PeptideAtlas; Q8TD19; -.
DR   PRIDE; Q8TD19; -.
DR   DNASU; 91754; -.
DR   Ensembl; ENST00000238616; ENSP00000238616; ENSG00000119638.
DR   GeneID; 91754; -.
DR   KEGG; hsa:91754; -.
DR   UCSC; uc001xrl.4; human.
DR   CTD; 91754; -.
DR   DisGeNET; 91754; -.
DR   GeneCards; NEK9; -.
DR   HGNC; HGNC:18591; NEK9.
DR   HPA; HPA001405; -.
DR   MalaCards; NEK9; -.
DR   MIM; 609798; gene.
DR   MIM; 614262; phenotype.
DR   MIM; 617022; phenotype.
DR   MIM; 617025; phenotype.
DR   neXtProt; NX_Q8TD19; -.
DR   OpenTargets; ENSG00000119638; -.
DR   PharmGKB; PA38593; -.
DR   eggNOG; KOG0589; Eukaryota.
DR   eggNOG; KOG1426; Eukaryota.
DR   eggNOG; ENOG410Y7JF; LUCA.
DR   GeneTree; ENSGT00760000118997; -.
DR   HOVERGEN; HBG039572; -.
DR   InParanoid; Q8TD19; -.
DR   KO; K20878; -.
DR   OMA; PTEAMGN; -.
DR   OrthoDB; EOG091G0181; -.
DR   PhylomeDB; Q8TD19; -.
DR   TreeFam; TF106472; -.
DR   Reactome; R-HSA-2980767; Activation of NIMA Kinases NEK9, NEK6, NEK7.
DR   Reactome; R-HSA-3301854; Nuclear Pore Complex (NPC) Disassembly.
DR   SignaLink; Q8TD19; -.
DR   SIGNOR; Q8TD19; -.
DR   ChiTaRS; NEK9; human.
DR   GeneWiki; NEK9; -.
DR   GenomeRNAi; 91754; -.
DR   PRO; PR:Q8TD19; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000119638; -.
DR   CleanEx; HS_NEK8; -.
DR   CleanEx; HS_NEK9; -.
DR   ExpressionAtlas; Q8TD19; baseline and differential.
DR   Genevisible; Q8TD19; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0007077; P:mitotic nuclear envelope disassembly; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR009091; RCC1/BLIP-II.
DR   InterPro; IPR000408; Reg_chr_condens.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00415; RCC1; 4.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50985; SSF50985; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50012; RCC1_3; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cell division;
KW   Coiled coil; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Kinase; Magnesium; Metal-binding; Mitosis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    979       Serine/threonine-protein kinase Nek9.
FT                                /FTId=PRO_0000086435.
FT   DOMAIN       52    308       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REPEAT      388    444       RCC1 1.
FT   REPEAT      445    498       RCC1 2.
FT   REPEAT      499    550       RCC1 3.
FT   REPEAT      551    615       RCC1 4.
FT   REPEAT      616    668       RCC1 5.
FT   REPEAT      669    726       RCC1 6.
FT   NP_BIND      58     66       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      732    891       Interaction with NEK6.
FT                                {ECO:0000269|PubMed:19001501}.
FT   COILED      892    939       {ECO:0000255}.
FT   COMPBIAS    752    760       Poly-Gly.
FT   COMPBIAS    765    888       Pro/Ser/Thr-rich.
FT   ACT_SITE    176    176       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      81     81       ATP.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      16     16       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      29     29       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      52     52       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES      76     76       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     210    210       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:27153399,
FT                                ECO:0000305|PubMed:14660563}.
FT   MOD_RES     254    254       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     331    331       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     333    333       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     741    741       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     801    801       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     832    832       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     868    868       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     869    869       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     886    886       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     944    944       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     978    978       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VARIANT     167    167       I -> T (in NC; increased
FT                                autophosphorylation at T-210).
FT                                {ECO:0000269|PubMed:27153399}.
FT                                /FTId=VAR_077801.
FT   VARIANT     429    429       R -> H (in dbSNP:rs10146482).
FT                                {ECO:0000269|PubMed:11864968,
FT                                ECO:0000269|PubMed:12056414,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_027900.
FT   VARIANT     573    573       I -> T (in NC; increased
FT                                autophosphorylation at T-210).
FT                                {ECO:0000269|PubMed:27153399}.
FT                                /FTId=VAR_077802.
FT   VARIANT     681    681       R -> H (in APUG; dbSNP:rs142859694).
FT                                {ECO:0000269|PubMed:26633546}.
FT                                /FTId=VAR_077803.
FT   VARIANT     828    828       P -> T (in dbSNP:rs36014869).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040926.
FT   VARIANT     870    870       P -> S (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040927.
FT   MUTAGEN      81     81       K->M: Loss of activity and
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:12101123}.
FT   MUTAGEN     210    210       T->A: Significant reduction of
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:11864968}.
FT   MUTAGEN     214    214       T->A: No effect on autophosphorylation.
FT                                {ECO:0000269|PubMed:11864968}.
FT   CONFLICT    351    351       V -> I (in Ref. 2; AAL87410).
FT                                {ECO:0000305}.
FT   CONFLICT    967    967       W -> G (in Ref. 2; AAL87410).
FT                                {ECO:0000305}.
FT   STRAND      942    948       {ECO:0000244|PDB:3ZKE}.
SQ   SEQUENCE   979 AA;  107168 MW;  8583FDDE599324A2 CRC64;
     MSVLGEYERH CDSINSDFGS ESGGCGDSSP GPSASQGPRA GGGAAEQEEL HYIPIRVLGR
     GAFGEATLYR RTEDDSLVVW KEVDLTRLSE KERRDALNEI VILALLQHDN IIAYYNHFMD
     NTTLLIELEY CNGGNLYDKI LRQKDKLFEE EMVVWYLFQI VSAVSCIHKA GILHRDIKTL
     NIFLTKANLI KLGDYGLAKK LNSEYSMAET LVGTPYYMSP ELCQGVKYNF KSDIWAVGCV
     IFELLTLKRT FDATNPLNLC VKIVQGIRAM EVDSSQYSLE LIQMVHSCLD QDPEQRPTAD
     ELLDRPLLRK RRREMEEKVT LLNAPTKRPR SSTVTEAPIA VVTSRTSEVY VWGGGKSTPQ
     KLDVIKSGCS ARQVCAGNTH FAVVTVEKEL YTWVNMQGGT KLHGQLGHGD KASYRQPKHV
     EKLQGKAIRQ VSCGDDFTVC VTDEGQLYAF GSDYYGCMGV DKVAGPEVLE PMQLNFFLSN
     PVEQVSCGDN HVVVLTRNKE VYSWGCGEYG RLGLDSEEDY YTPQKVDVPK ALIIVAVQCG
     CDGTFLLTQS GKVLACGLNE FNKLGLNQCM SGIINHEAYH EVPYTTSFTL AKQLSFYKIR
     TIAPGKTHTA AIDERGRLLT FGCNKCGQLG VGNYKKRLGI NLLGGPLGGK QVIRVSCGDE
     FTIAATDDNH IFAWGNGGNG RLAMTPTERP HGSDICTSWP RPIFGSLHHV PDLSCRGWHT
     ILIVEKVLNS KTIRSNSSGL SIGTVFQSSS PGGGGGGGGG EEEDSQQESE TPDPSGGFRG
     TMEADRGMEG LISPTEAMGN SNGASSSCPG WLRKELENAE FIPMPDSPSP LSAAFSESEK
     DTLPYEELQG LKVASEAPLE HKPQVEASSP RLNPAVTCAG KGTPLTPPAC ACSSLQVEVE
     RLQGLVLKCL AEQQKLQQEN LQIFTQLQKL NKKLEGGQQV GMHSKGTQTA KEEMEMDPKP
     DLDSDSWCLL GTDSCRPSL
//
